Compare BridgeBio Pharma Inc (BBIO) vs Grab Holdings Ltd. (GRAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Grab Holdings Ltd. — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.27B), while Grab Holdings Ltd. trades at $3.8 (market cap $16.11B). The key difference: BridgeBio Pharma Inc and Grab Holdings Ltd. are close in size by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals.
| BBIO | GRAB | |
|---|---|---|
Market Cap | $16.27B | $16.11B |
Sector | Health | Technology |
52-Week High | $90.17 | $6.45 |
52-Week Low | $44.81 | $3.27 |
Enterprise Value | $17.82B | $11.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GRAB trades at $3.94, up 0.25% on the day, with a bullish technical signal and strong analyst support. The company achieved profitability in 2025 with $268M net income and 7.95% margin, showing significant improvement from prior losses. Revenue growth continues, reaching $3.37B in 2025. Recent news highlights market outperformance and investor attention, though the stock reacted negatively to Uber CEO's board departure in early July 2026.
Outlook remains positive with 91.67% analyst buy ratings and $5.45 consensus target, implying 38% upside. Key risks include competitive pressures in ride-hailing, execution challenges in expanding financial services, and potential market volatility. Profitability trajectory and cash flow sustainability are critical for maintaining investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →
